Top Atlanta, GA Health Tech Companies With Best Stability & Growth (209)

Market Expansion: Footprint growth from 120+ customers across 14 states in mid-2023 to "20+ states served" with 17,700+ completed requests and 8,800+ patients by 2025 indicates ongoing geographic and usage expansion.

Innovation-Driven Growth: A new partner portal effective May 1, 2026, together with a granted platform patent and AI-enabled request intake, points to continuous product development supporting scale.

Strategic Partnerships: Engagements with large health systems (e.g., an ongoing rollout across Emory Healthcare) and active onboarding of transportation partners suggest a strengthening ecosystem to drive growth.

Strong Revenue Growth: Consolidated revenues increased from $253 billion in 2024 to $270.6 billion in 2025, with quarterly gains such as Q4 2025 up 8% year over year. Growth was led primarily by Optum Rx and supported by steady contributions from Optum Insight.

Market Expansion: Expansion through acquisitions such as Holston Medical Group (August 2025) and Alegeus (July 2026), alongside earlier combinations like Change Healthcare and Atrius Health, broadened capabilities across care, pharmacy, and payments. These moves extend Optum’s platform into adjacent services and operating domains.

Diversified Revenue Streams: A multi-segment model—Rx, Insight, and Health—helps sustain aggregate growth even as individual lines vary, with pharmacy and technology businesses offsetting care-delivery softness. Parent-company commentary continuing to frame Optum as a growth engine and raising 2026 guidance underscores the benefit of this portfolio effect.

Market Expansion: Headcount and footprint are described as rising to more than 15,000 employees across 40-plus offices, alongside concrete new sites in Hyderabad and a completed Chicago buildout—signals of geographic and capacity expansion. These moves indicate confidence in demand across key delivery hubs.

Innovation-Driven Growth: A dedicated Platforms & Products unit, the ZAIDYN portfolio, and AI-agent initiatives point to sustained investment in productized, AI-enabled offerings. Capability-deepening acquisitions (Digital Additive in 2024 and Torrent Consulting in 2025) further strengthen CRM and multi‑cloud life‑sciences solutions.

Strategic Partnerships: An expanded Salesforce collaboration around Agentforce and recognition as Databricks 2025 Life Sciences Partner of the Year suggest momentum in data/AI ecosystems. These alliances position the firm to capture spend where CRM, data, and AI converge in healthcare and life sciences.

Strong Revenue Growth: Repeated Inc. 5000 recognition through 2025–2026 points to sustained multi‑year top‑line expansion. This ongoing external acknowledgement aligns with signals of continued growth momentum.

Market Expansion: The acquisition of Joshin in 2025 extends the platform into integrated neurodiversity and disability support, broadening the company’s reach beyond its historical software footprint. Partnerships and integrations with adjacent platforms further widen distribution and cross‑sell opportunities.

Innovation-Driven Growth: Multiple 2026 launches—Session Note AI, an AI Dashboard for ABA operations, and BillAI—illustrate a rapid product cadence aimed at deepening adoption and upsell. This pace of releases underscores continued investment in AI and workflow automation.

Strong Revenue Growth: Revenue is expanding at a sustained, double‑digit pace across 2024–2026, and management’s 2026 outlook signals further increases from 2025 levels. Multiple consecutive quarters show acceleration, reinforcing momentum rather than a one‑off spike.

Profitability: Adjusted EBITDA margins remained strong while scaling, indicating operating leverage alongside topline expansion. Management also references accretive potential from recent actions that could support margins over time.

Customer Loyalty & Retention: Net revenue retention remained well above 100%, and the number of larger clients increased, pointing to expansion within the installed base. These dynamics suggest durable relationships that can compound growth via cross‑sell and upsell.

Strong Revenue Growth: Recent quarters show accelerated top-line expansion with management increasing full-year growth guidance. Momentum reflects both organic gains and contributions from recent acquisitions.

Profitability: Operating metrics indicate healthy margins and rising earnings alongside revenue growth. Commentary highlights disciplined execution during peak demand periods while maintaining margin targets.

Innovation-Driven Growth: AI-led solutions, analytics, and automation are cited as material drivers of wins and efficiency across payer and provider workflows. New offerings and deployed AI use cases appear to be supporting scale and client expansion.

Strong Market Position & Advantage: The company is described as the global leader in dialysis services and products, reinforced by a large clinic footprint and dominance in key product categories. A vertically integrated model across care delivery and manufacturing underpins scale advantages.

Strong Revenue Growth: Recent periods show consistent organic growth across segments with accelerating momentum and confirmed positive guidance. Expansion in value-based care and pricing, alongside steady treatment volumes, supports this trajectory.

Cost & Operational Efficiency: Transformation programs are delivering substantial savings that are expanding margins and improving profitability. Operational initiatives and portfolio optimization are described as driving a structural earnings reset.

Strong Market Position & Advantage: Elsevier is widely regarded as a dominant force in STM publishing with flagship journals (e.g., The Lancet, Cell) and critical platforms like ScienceDirect and Scopus. Feedback suggests this entrenched position supports stable demand and reinforces its central role in research and clinical workflows.

Profitability: The business delivers strong profits with high operating margins and contributes materially to its parent company’s earnings. Feedback suggests profitability has remained robust alongside increased article output and heavy platform usage.

Innovation-Driven Growth: The company is shifting toward higher-growth analytics and AI-enabled tools and expanding through targeted healthcare tech acquisitions. Feedback suggests rapid growth in open access output and new AI-assisted research tools positions the business well for future demand.

Strategic Partnerships: A five-year, enterprise-wide agreement keeps ChenMed in-network with Humana’s Medicare Advantage plans across all brands, signaling durable payer alignment.

Strong Market Position & Advantage: The company is described as a recognized leader in full‑risk, senior‑focused primary care with a sizable national footprint of 100+ centers across roughly 15 states, placing it among the small cohort that has scaled the model.

Cost & Operational Efficiency: Management has shifted from hypergrowth to a “pause and prune” approach, rightsizing and selectively closing underperforming or overlapping sites to sharpen operating discipline.

Strong Market Position & Advantage: Industry and company materials indicate ResMed is the leading player in global sleep‑apnea devices and masks, supported by scale and a large connected ecosystem (AirView/myAir). Philips’ U.S. consent decree and extended remediation have provided a multi‑year window that reinforced ResMed’s relative momentum.

Strong Revenue Growth: Recent quarters show continued year‑over‑year revenue growth with margin expansion, driven by device demand and recurring masks/accessories. Management commentary and investor materials point to sustained momentum through FY2026 to date.

Diversified Revenue Streams: A large installed base of connected devices underpins recurring resupply revenue and remote monitoring workflows. Ownership of Brightree and MatrixCare adds out‑of‑hospital software that complements the core hardware franchise.